Akso Health Group (HX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Akso Health Group (HX) trades at $2.24 with AI Score 38/100 (Grade D). Akso Health Group Inc. , formerly Hexindai Inc. , operates an online marketplace connecting borrowers and investors. Market cap: $53.4M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HX: HX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HX: 3/3 scored disciplines lean bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Akso Health Group (HX) Healthcare & Pipeline Overview
Akso Health Group, formerly Hexindai, operates an online marketplace connecting borrowers and investors, primarily serving the emerging middle class in China with tailored loan products; however, its negative profit and gross margins raise concerns about its financial sustainability in the competitive medical distribution sector.
What Is the Investment Thesis for HX?
Akso Health Group presents a speculative investment case due to its current financial metrics. With a negative P/E ratio of -5.70 and a significantly negative profit margin of -1190.8%, the company's profitability is a major concern. The company's gross margin is also negative, at -3.3%. The company's high beta of 1.47 indicates higher volatility compared to the market. While the company aims to serve the growing middle class in China with tailored loan products, its financial performance raises questions about its long-term sustainability. Investors should carefully consider the risks associated with the company's financial instability and competitive landscape before making any investment decisions. The absence of a dividend yield further reduces the attractiveness of the stock for income-seeking investors.
Based on FMP financials and quantitative analysis
HX Key Highlights
Market capitalization of $53.4M, indicating a small-cap company.
- Negative P/E ratio of -5.70, reflecting the company's lack of profitability.
- Profit margin of -1190.8%, highlighting significant losses.
- Gross margin of -3.3%, indicating challenges in generating revenue exceeding the cost of goods sold.
- Beta of 1.47, suggesting higher volatility compared to the overall market.
Who Are HX's Competitors?
HX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALR AlerisLife Inc. | $1.32 | +0.00% | $44.2M | 39 |
| ALVR AlloVir, Inc. | $9.81 | +4.14% | $49.5M | 46 |
| BNKK Bonk, Inc. | $1.03 | -2.83% | $8.24M | — |
| EAR Eargo, Inc. | $2.57 | -4.10% | $53.4M | 53 |
| HTBX Heat Biologics, Inc. | $2.38 | +0.42% | $61.1M | 48 |
| GEG Great Elm Group, Inc. | $2.15 | +0.00% | $67.4M | — |
| ACH Accendra Health, Inc. (ACH) is a healthcare solutions company providing products and services to healthcare providers and patients. The company | $1.31 | -0.76% | $100M | — |
| CQCQ MakingORG, Inc. | $0.75 | +0.00% | $26.7M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HX's Key Strengths?
Online marketplace platform.
- Tailored loan products.
- Focus on the emerging middle class in China.
What Are HX's Weaknesses?
Negative profit margin.
- Negative gross margin.
- Small market capitalization.
What Could Drive HX Stock Higher?
Potential partnerships with healthcare providers to expand service offerings.
- Development and launch of new financial products tailored to the healthcare sector.
- Expansion of the online marketplace platform to reach a wider customer base.
What Are the Key Risks for HX?
Financial-distress signal — its Altman Z-Score of -8.19 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-67.6%) — the business is not currently generating profit on shareholder capital.
- Negative profit and gross margins raise concerns about financial sustainability.
- Regulatory changes in China could impact the company's operations.
- Economic downturn could affect borrowers' ability to repay loans.
- Intense competition in the financial services industry could limit growth opportunities.
What Are the Growth Opportunities for HX?
- Expansion into new healthcare segments: Akso Health Group can explore opportunities in telemedicine, online pharmacies, and other digital health services. The global telemedicine market is projected to reach $431.82 billion by 2030, growing at a CAGR of 32.7% from 2023 to 2030. By leveraging its online platform and customer base, Akso Health Group can diversify its revenue streams and capitalize on the growing demand for digital health solutions. This expansion could be realized within the next 2-3 years.
- Strategic partnerships with healthcare providers: Collaborating with hospitals, clinics, and other healthcare providers can enable Akso Health Group to offer integrated financial solutions to patients. This could include financing options for medical treatments, insurance products, and other healthcare-related expenses. By partnering with established healthcare providers, Akso Health Group can gain access to a wider customer base and enhance its credibility in the market. These partnerships could be established within the next 1-2 years.
- Development of innovative financial products: Akso Health Group can invest in developing new financial products tailored to the specific needs of the healthcare sector. This could include loans for medical equipment purchases, financing for healthcare startups, and insurance products for healthcare professionals. By offering innovative and customized financial solutions, Akso Health Group can differentiate itself from competitors and attract new customers. These new products could be launched within the next 2-3 years.
- Geographic expansion within China: While currently focused on the emerging middle class in China, Akso Health Group can expand its reach to other regions and demographic segments. This could involve targeting underserved rural areas or offering specialized financial products to specific industries. By expanding its geographic footprint, Akso Health Group can tap into new markets and increase its overall revenue potential. This expansion could be phased in over the next 3-5 years.
- Leveraging data analytics for personalized services: Akso Health Group can utilize data analytics to gain deeper insights into customer needs and preferences. This can enable the company to offer personalized financial solutions, improve risk assessment, and enhance customer engagement. By leveraging data analytics, Akso Health Group can optimize its operations and provide a more tailored experience for its customers. Implementation of advanced analytics could begin within the next year.
What Are HX's Competitive Advantages?
- Online marketplace platform connecting borrowers and investors.
- Tailored loan products designed for the emerging middle class in China.
- Proprietary customer segmentation data for targeted marketing.
What Does HX Do?
Akso Health Group Inc., formerly known as Hexindai Inc., is a holding company that operates an online marketplace connecting borrowers and investors. Founded with the aim of serving the emerging middle class in China, the company provides a platform for individuals to access tailored loan products. These products are designed based on customer segmentation data to meet the specific needs of this demographic. The company's headquarters are located in Beijing, China. Akso Health Group offers a range of loan products, including Provident Fund Loans, Property-Owner Loans, Car-Owner Loans, Insurance-Holder Loans, and Premier Customer Loans. These products cater to different segments of the borrower market, providing options for individuals with varying asset ownership and financial profiles. The company serves both borrowers and investors through its online platform. As of 2026, Akso Health Group employs 113 individuals.
What Products and Services Does HX Offer?
- Operates an online marketplace connecting borrowers and investors.
- Offers tailored loan products to the emerging middle class in China.
- Provides Provident Fund Loans.
- Provides Property-Owner Loans.
- Provides Car-Owner Loans.
- Provides Insurance-Holder Loans.
- Provides Premier Customer Loans.
How Does HX Make Money?
- Connects borrowers and investors through an online platform.
- Generates revenue through fees and interest on loans.
- Offers tailored loan products based on customer segmentation data.
What Industry Does HX Operate In?
Akso Health Group operates within the medical distribution sector, which is experiencing growth driven by increased healthcare spending and demand for medical products and services. However, the industry is highly competitive, with numerous players vying for market share. Akso Health Group's online marketplace model aims to differentiate itself by connecting borrowers and investors, but it faces competition from traditional financial institutions and other online lending platforms. The company's financial performance, as indicated by its negative profit and gross margins, raises concerns about its ability to compete effectively in the industry.
Who Are HX's Key Customers?
- Emerging middle class in China seeking loans.
- Investors looking for investment opportunities.
- Borrowers with varying asset ownership and financial profiles.
Company Profile
Akso Health Group operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Xiaobo An. HX has traded publicly since 2017.
Akso Health Group (HX) Valuation Context
Valued at $53.4M, HX is classified as a micro-cap stock. Relative to its peer group, HX's quantitative score of 38/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Return on equity for Akso Health Group stands at -67.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -63.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -27.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Akso Health Group's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -8.19 places it in the distress zone, a signal of elevated financial risk.
HX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in Akso Health's future, suggesting that key stakeholders believe in the company's growth potential.
- Community sentiment has shown a notable increase in positive discussions around Akso Health's innovative health solutions, reflecting growing interest.
- Recent partnerships and collaborations have been highlighted, indicating a strategic move to enhance market reach and product offerings.
- The healthcare sector's ongoing demand for innovative solutions positions Akso Health favorably in a growing market.
Bear Case
- Concerns have been raised about regulatory challenges facing the healthcare industry, which could impact Akso Health's operations and growth trajectory.
- Negative sentiment has emerged from discussions around competition, with some analysts pointing to emerging rivals that may threaten market share.
- Recent earnings reports have not met community expectations, leading to skepticism about the company's short-term performance.
- Market perception has been tempered by broader economic uncertainties, which could influence investor confidence in Akso Health's stability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HX Latest News
No recent news available for HX.
HX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HX.
Price Targets
Wall Street price target analysis for HX.
HX MoonshotScore
What does this score mean?
The MoonshotScore rates HX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Xiaobo An
CEO
Xiaobo An is the CEO of Akso Health Group, managing a team of 113 employees. Information regarding Xiaobo An's prior experience and educational background is not available. As CEO, Xiaobo An is responsible for the overall strategic direction and management of the company, including overseeing the online marketplace operations and the development of tailored loan products for the emerging middle class in China.
Track Record: Information regarding Xiaobo An's specific achievements and strategic decisions as CEO of Akso Health Group is not available. The company's recent financial performance, characterized by negative profit and gross margins, presents a significant challenge for the CEO.
Akso Health Group ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. HX, as an ADR, allows U.S. investors to invest in Akso Health Group, a Chinese company, without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars, simplifying trading and price discovery for U.S. investors.
- Home Market Ticker: The primary stock exchange for Akso Health Group's domestic shares is in China.
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About HX (Healthcare)
What does the AI Score mean for HX?
HX holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Akso Health Group Inc., formerly Hexindai Inc., operates an online marketplace connecting borrowers and investors. The company focuses on providing tailored loan products to the emerging middle …
What does Akso Health Group do?
Akso Health Group operates an online marketplace connecting borrowers and investors, primarily focusing on serving the emerging middle class in China. The company offers tailored loan products, including Provident Fund Loans, Property-Owner Loans, Car-Owner Loans, Insurance-Holder Loans, and Premier Customer Loans. These products are designed to meet the specific financial needs of this demographic.
What do analysts say about HX stock?
As of March 17, 2026, a comprehensive analyst consensus on Akso Health Group (HX) is not readily available. The company's financial metrics, including a negative P/E ratio and significantly negative profit and gross margins, suggest caution. Investors should conduct thorough due diligence and consider the risks associated with the company's financial instability and competitive landscape. Further analyst coverage and updated financial data are needed to form a more informed opinion.
What are the main risks for HX?
The main risks for Akso Health Group include its negative profit and gross margins, which raise concerns about its ability to generate sustainable revenue. The company also faces regulatory risks in China, as changes in government policies could impact its operations. Additionally, an economic downturn could affect borrowers' ability to repay loans, leading to increased defaults and financial losses.
What are the key factors to evaluate for HX?
Akso Health Group (HX) holds an AI score of 38/100 (low). Akso Health Group presents a speculative investment case due to its current financial metrics. Not financial advice.
How frequently does HX data refresh on this page?
HX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HX's recent stock price performance?
Akso Health Group (HX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Online marketplace platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HX overvalued or undervalued right now?
Akso Health Group (HX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HX before investing?
Before investing in Akso Health Group (HX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide further insights.
- Information regarding CEO track record is limited.